KU-60019: Unlocking Metabolic Vulnerabilities in Glioma v...
2025-10-18
Discover how KU-60019, a selective ATM kinase inhibitor, unveils novel metabolic vulnerabilities in glioma by integrating DNA damage response inhibition with advanced metabolic reprogramming. This article offers a unique framework for leveraging KU-60019 in cancer research beyond radiosensitization.